Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Application of Bio-Molecular Sciences in Peritoneal Dialysis 2.0
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Application of Bio-Molecular Sciences in Peritoneal Dialysis 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 15710

Special Issue Editor

Dr. Silvio Borrelli

E-Mail Website
Guest Editor
Unit of Nephrology, Department of Advanced Surgical and Medical Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia, 80138 Naples, Italy
Interests: kidney disease; peritoneal dialysis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the continuation of our previous Special Issue, “Application of Bio-Molecular Sciences in Peritoneal Dialysis”.

The prevalence of End Stage Kidney Disease (ESKD) is growing in these last years, due to the aging of the general population and increased prevalence of diabetes and cardiovascular (CV) diseases. This "great wave" of frail elderly patients in need of renal replacement therapy (RRT) poses concerns about the quality of chronic care and economic sustainability. Furthermore, recent pandemic by Coronavirus Covid-19 has highlighted the need to enhance domiciliary care in ESKD patients.

Peritoneal Dialysis (PD) is the most popular home dialysis, representing, however, only 10% of total RRT in Western countries, though no difference in mortality and treatment adequacy was evident, in the face of lower economic burden. Therefore, a wider “PD culture” is desirable in Nephrology world, and not only.

The main aim of this special issue of International Journal of Molecular Science is to provide an update about current knowledge and future perspectives for the treatment of metabolic alterations occurring in ESKD patients. More specifically, we will focus on the recent promising insights about PD that may improve further dialysis efficacy, reducing local and systemic side effects of this treatment.

Potential Topics:

  • Sodium and water in peritoneal dialysis: Mechanisms and solutions
  • Hyperkaliemia in End Stage Kidney Disease: the role of novel therapies.
  • Mineral Bone disease in End Stage Kidney Disease: “Klotho and his brothers”.
  • HIF stabilizers in End Stage Kidney Disease: “every promise is a debt”
  • Fibrosis of peritoneal membrane: target of new therapies in peritoneal dialysis?
  • Glucose load and Insulin-sensitivity in peritoneal dialysis
  • MicroRNAs in dialysis: What future?
  • Proteomics in End Stage Kidney Disease: is there room for it in Nephrology?

Dr. Silvio Borrelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • End Stage Kidney Disease (ESKD)
  • Peritoneal Dialysis (PD)
  • hyperkaliemia
  • mineral bone disease
  • nephrology

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

24 pages, 920 KiB  
Review
Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic
by Lilio Hu, Angelodaniele Napoletano, Michele Provenzano, Carlo Garofalo, Claudia Bini, Giorgia Comai and Gaetano La Manna
Int. J. Mol. Sci. 2022, 23(20), 12223; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232012223 - 13 Oct 2022
Cited by 18 | Viewed by 12135
Abstract
Chronic kidney disease (CKD) is a complex and multifactorial disease, and one of the most prevalent worldwide. Chronic kidney disease–mineral bone disorders (CKD–MBD) with biochemical and hormonal alterations are part of the complications associated with the progression of CKD. Pathophysiology of CKD–MBD focused [...] Read more.
Chronic kidney disease (CKD) is a complex and multifactorial disease, and one of the most prevalent worldwide. Chronic kidney disease–mineral bone disorders (CKD–MBD) with biochemical and hormonal alterations are part of the complications associated with the progression of CKD. Pathophysiology of CKD–MBD focused on abnormalities in serum levels of several biomarkers (such as FGF-23, klotho, phosphate, calcium, vitamin D, and PTH) which are discussed in this review. We therefore examine the prognostic association between CKD–MBD and the increased risk for cardiovascular events, mortality, and CKD progression to end-stage kidney disease (ESKD). Lastly, we present specific treatments acting on CKD to prevent and treat the complications associated with secondary hyperparathyroidism (SHPT): control of hyperphosphatemia (with dietary restriction, intestinal phosphate binders, and adequate dialysis), the use of calcimimetic agents, vitamin D, and analogues, and the use of bisphosphonates or denosumab in patients with osteoporosis. Full article
(This article belongs to the Special Issue Application of Bio-Molecular Sciences in Peritoneal Dialysis 2.0)
►▼ Show Figures

Figure 1

13 pages, 738 KiB  
Review
Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers
by Silvio Borrelli, Ida Matarazzo, Eugenio Lembo, Laura Peccarino, Claudia Annoiato, Maria Rosaria Scognamiglio, Andrea Foderini, Chiara Ruotolo, Aldo Franculli, Federica Capozzi, Pavlo Yavorskiy, Fatme Merheb, Michele Provenzano, Gaetano La Manna, Luca De Nicola, Roberto Minutolo and Carlo Garofalo
Int. J. Mol. Sci. 2022, 23(12), 6378; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23126378 - 07 Jun 2022
Cited by 5 | Viewed by 3180
Abstract
Increasing potassium intake ameliorates blood pressure (BP) and cardiovascular (CV) prognoses in the general population; therefore the World Health Organization recommends a high-potassium diet (90–120 mEq/day). Hyperkalaemia is a rare condition in healthy individuals due to the ability of the kidneys to effectively [...] Read more.
Increasing potassium intake ameliorates blood pressure (BP) and cardiovascular (CV) prognoses in the general population; therefore the World Health Organization recommends a high-potassium diet (90–120 mEq/day). Hyperkalaemia is a rare condition in healthy individuals due to the ability of the kidneys to effectively excrete dietary potassium load in urine, while an increase in serum K+ is prevalent in patients with chronic kidney disease (CKD). Hyperkalaemia prevalence increases in more advanced CKD stages, and is associated with a poor prognosis. This scenario generates controversy on the correct nutritional approach to hyperkalaemia in CKD patients, considering the unproven link between potassium intake and serum K+ levels. Another concern is that drug-induced hyperkalaemia leads to the down-titration or withdrawal of renin-angiotensin system inhibitors (RASI) and mineralocorticoids receptors antagonists (MRA) in patients with CKD, depriving these patients of central therapeutic interventions aimed at delaying CKD progression and decreasing CV mortality. The new K+-binder drugs (Patiromer and Sodium-Zirconium Cyclosilicate) have proven to be adequate and safe therapeutic options to control serum K+ in CKD patients, enabling RASI and MRA therapy, and possibly, a more liberal intake of fruit and vegetables. Full article
(This article belongs to the Special Issue Application of Bio-Molecular Sciences in Peritoneal Dialysis 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop